$ELAB announced that Northstrive Biosciences will present its lead asset, EL-22, a first-in-class engineered probiotic for muscle preservation during weight loss, at UCLA's Anti-Obesity Treatments symposium, organized by UCLA Metabolism Theme.

See More Biotech Updates👇$ALUR $AKRO $NVO $VINC $XFOR $SMLR $REVB $DRMA
#ELAB